A Novel Compound Heterozygous Tyrosine Hydroxylase Mutation (p.R441P) with Complex Phenotype
Author(s) -
Kristoffer Haugarvoll,
Laurence A. Bindoff
Publication year - 2011
Publication title -
journal of parkinson s disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.747
H-Index - 45
eISSN - 1877-718X
pISSN - 1877-7171
DOI - 10.3233/jpd-2011-11006
Subject(s) - tyrosine hydroxylase , tetrahydrobiopterin , missense mutation , compound heterozygosity , dystonia , phenotype , phenylalanine hydroxylase , mutation , tyrosine , tyrosine 3 monooxygenase , gtp cyclohydrolase i , genetics , gene , enzyme , dopamine , biology , endocrinology , biochemistry , nitric oxide synthase , phenylalanine , amino acid , neuroscience
Tyrosine hydroxylase (TH) is a tetrahydrobiopterin (BH4) dependent enzyme that catalyses the conversion of L-tyrosine to L-dopa, the rate-limiting step in the biosynthesis of dopamine. Autosomal recessive mutations in the TH gene cause impaired TH activity and are associated with phenotypes ranging from autosomal recessive dopa-responsive dystonia (DRD) to progressive infantile encephalopathy. Herein, we present a patient with TH-deficiency due to two compound heterozygous missense mutations in the TH/gene, one of which is novel (p.R441P). A clinical update on TH-deficiency and clues on how to achieve a timely diagnosis of this highly treatable disorder is provided.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom